Utilization of anti‐Parkinson drugs in Australia: 1995–2009
Identifieur interne : 000B77 ( Main/Corpus ); précédent : 000B76; suivant : 000B78Utilization of anti‐Parkinson drugs in Australia: 1995–2009
Auteurs : Samantha A. Hollingworth ; Amanda Rush ; Wayne D. Hall ; Mervyn J. EadieSource :
- Pharmacoepidemiology and Drug Safety [ 1053-8569 ] ; 2011-05.
English descriptors
Abstract
Purpose: To examine trends in the prescribing of anti‐Parkinsonian drugs (APD) in Australia from 1995 to 2009. Methods: We analyzed the Medicare Australia and Drug Utilisation Sub‐Committee (DUSC) databases for prescription data for overall APD dispensed use from 1995. We were able to examine prescribing by gender, age, and type of prescriber between 2002 and 2009. Prescriptions were converted to defined daily doses (DDD)/1000 population/day using Australian Bureau of Statistics population data. Results: Dispensed use of levodopa + carbidopa remained steady from 1995 to 2009 (0.76–0.82 DDD/1000 population/day); levodopa + benserazide use increased from 0.34 to 0.55 DDD/1000 population/day. Since 2005 dispensed use of levodopa + carbidopa + entacapone has steadily increased, from 0.03 to 0.10 DDD/1000 population/day. In July 2009 levodopa + carbidopa was the most widely used agent, followed by levodopa + benserazide, then benztropine. Cabergoline increased from 1999, peaked in 2006, and thereafter declined. APD use peaked in males and females aged 60–69 years. Age‐adjusted utilization was slightly higher in males than females. Conclusions: The amount of levodopa dispensed has slowly increased with levodopa + benserazide increasing faster than levodopa + carbidopa. Use of cabergoline fell when pramipexole became available and the risk of ergot‐related serosal adverse effects was more widely appreciated. Use of centrally acting anti‐cholinergics decreased over a period of time when use of atypical anti‐psychotic agents increased. Copyright © 2011 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/pds.2114
Links to Exploration step
ISTEX:E6859C2E262862C6FD9A0C74E7103DF47E68A69CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Utilization of anti‐Parkinson drugs in Australia: 1995–2009</title><author><name sortKey="Hollingworth, Samantha A" sort="Hollingworth, Samantha A" uniqKey="Hollingworth S" first="Samantha A" last="Hollingworth">Samantha A. Hollingworth</name><affiliation><mods:affiliation>The University of Queensland, School of Population Health, Herston, Australia</mods:affiliation></affiliation></author><author><name sortKey="Rush, Amanda" sort="Rush, Amanda" uniqKey="Rush A" first="Amanda" last="Rush">Amanda Rush</name><affiliation><mods:affiliation>The University of Queensland, School of Population Health, Herston, Australia</mods:affiliation></affiliation></author><author><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D" last="Hall">Wayne D. Hall</name><affiliation><mods:affiliation>The University of Queensland, UQ Centre for Clinical Research, Herston, Australia</mods:affiliation></affiliation></author><author><name sortKey="Eadie, Mervyn J" sort="Eadie, Mervyn J" uniqKey="Eadie M" first="Mervyn J" last="Eadie">Mervyn J. Eadie</name><affiliation><mods:affiliation>The University of Queensland, School of Medicine, Herston, Australia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E6859C2E262862C6FD9A0C74E7103DF47E68A69C</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/pds.2114</idno><idno type="url">https://api.istex.fr/document/E6859C2E262862C6FD9A0C74E7103DF47E68A69C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B77</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Utilization of anti‐Parkinson drugs in Australia: 1995–2009</title><author><name sortKey="Hollingworth, Samantha A" sort="Hollingworth, Samantha A" uniqKey="Hollingworth S" first="Samantha A" last="Hollingworth">Samantha A. Hollingworth</name><affiliation><mods:affiliation>The University of Queensland, School of Population Health, Herston, Australia</mods:affiliation></affiliation></author><author><name sortKey="Rush, Amanda" sort="Rush, Amanda" uniqKey="Rush A" first="Amanda" last="Rush">Amanda Rush</name><affiliation><mods:affiliation>The University of Queensland, School of Population Health, Herston, Australia</mods:affiliation></affiliation></author><author><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D" last="Hall">Wayne D. Hall</name><affiliation><mods:affiliation>The University of Queensland, UQ Centre for Clinical Research, Herston, Australia</mods:affiliation></affiliation></author><author><name sortKey="Eadie, Mervyn J" sort="Eadie, Mervyn J" uniqKey="Eadie M" first="Mervyn J" last="Eadie">Mervyn J. Eadie</name><affiliation><mods:affiliation>The University of Queensland, School of Medicine, Herston, Australia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmacoepidemiology and Drug Safety</title><title level="j" type="abbrev">Pharmacoepidem. Drug Safe.</title><idno type="ISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><imprint><publisher>John Wiley & Sons, Ltd</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2011-05">2011-05</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="450">450</biblScope><biblScope unit="page" to="456">456</biblScope></imprint><idno type="ISSN">1053-8569</idno></series><idno type="istex">E6859C2E262862C6FD9A0C74E7103DF47E68A69C</idno><idno type="DOI">10.1002/pds.2114</idno><idno type="ArticleID">PDS2114</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1053-8569</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>anti‐Parkinson drugs</term><term>pharmacoepidemiology</term><term>prescribing</term><term>utilization</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose: To examine trends in the prescribing of anti‐Parkinsonian drugs (APD) in Australia from 1995 to 2009. Methods: We analyzed the Medicare Australia and Drug Utilisation Sub‐Committee (DUSC) databases for prescription data for overall APD dispensed use from 1995. We were able to examine prescribing by gender, age, and type of prescriber between 2002 and 2009. Prescriptions were converted to defined daily doses (DDD)/1000 population/day using Australian Bureau of Statistics population data. Results: Dispensed use of levodopa + carbidopa remained steady from 1995 to 2009 (0.76–0.82 DDD/1000 population/day); levodopa + benserazide use increased from 0.34 to 0.55 DDD/1000 population/day. Since 2005 dispensed use of levodopa + carbidopa + entacapone has steadily increased, from 0.03 to 0.10 DDD/1000 population/day. In July 2009 levodopa + carbidopa was the most widely used agent, followed by levodopa + benserazide, then benztropine. Cabergoline increased from 1999, peaked in 2006, and thereafter declined. APD use peaked in males and females aged 60–69 years. Age‐adjusted utilization was slightly higher in males than females. Conclusions: The amount of levodopa dispensed has slowly increased with levodopa + benserazide increasing faster than levodopa + carbidopa. Use of cabergoline fell when pramipexole became available and the risk of ergot‐related serosal adverse effects was more widely appreciated. Use of centrally acting anti‐cholinergics decreased over a period of time when use of atypical anti‐psychotic agents increased. Copyright © 2011 John Wiley & Sons, Ltd.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Samantha A Hollingworth</name><affiliations><json:string>The University of Queensland, School of Population Health, Herston, Australia</json:string></affiliations></json:item><json:item><name>Amanda Rush</name><affiliations><json:string>The University of Queensland, School of Population Health, Herston, Australia</json:string></affiliations></json:item><json:item><name>Wayne D Hall</name><affiliations><json:string>The University of Queensland, UQ Centre for Clinical Research, Herston, Australia</json:string></affiliations></json:item><json:item><name>Mervyn J Eadie</name><affiliations><json:string>The University of Queensland, School of Medicine, Herston, Australia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>anti‐Parkinson drugs</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>utilization</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>prescribing</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pharmacoepidemiology</value></json:item></subject><articleId><json:string>PDS2114</json:string></articleId><language><json:string>eng</json:string></language><abstract>Purpose: To examine trends in the prescribing of anti‐Parkinsonian drugs (APD) in Australia from 1995 to 2009. Methods: We analyzed the Medicare Australia and Drug Utilisation Sub‐Committee (DUSC) databases for prescription data for overall APD dispensed use from 1995. We were able to examine prescribing by gender, age, and type of prescriber between 2002 and 2009. Prescriptions were converted to defined daily doses (DDD)/1000 population/day using Australian Bureau of Statistics population data. Results: Dispensed use of levodopa + carbidopa remained steady from 1995 to 2009 (0.76–0.82 DDD/1000 population/day); levodopa + benserazide use increased from 0.34 to 0.55 DDD/1000 population/day. Since 2005 dispensed use of levodopa + carbidopa + entacapone has steadily increased, from 0.03 to 0.10 DDD/1000 population/day. In July 2009 levodopa + carbidopa was the most widely used agent, followed by levodopa + benserazide, then benztropine. Cabergoline increased from 1999, peaked in 2006, and thereafter declined. APD use peaked in males and females aged 60–69 years. Age‐adjusted utilization was slightly higher in males than females. Conclusions: The amount of levodopa dispensed has slowly increased with levodopa + benserazide increasing faster than levodopa + carbidopa. Use of cabergoline fell when pramipexole became available and the risk of ergot‐related serosal adverse effects was more widely appreciated. Use of centrally acting anti‐cholinergics decreased over a period of time when use of atypical anti‐psychotic agents increased. Copyright © 2011 John Wiley & Sons, Ltd.</abstract><qualityIndicators><score>6.131</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595 x 791 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1593</abstractCharCount><pdfWordCount>3551</pdfWordCount><pdfCharCount>23522</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>215</abstractWordCount></qualityIndicators><title>Utilization of anti‐Parkinson drugs in Australia: 1995–2009</title><genre><json:string>article</json:string></genre><host><volume>20</volume><publisherId><json:string>PDS</json:string></publisherId><pages><total>7</total><last>456</last><first>450</first></pages><issn><json:string>1053-8569</json:string></issn><issue>5</issue><subject><json:item><value>Original Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1099-1557</json:string></eissn><title>Pharmacoepidemiology and Drug Safety</title><doi><json:string>10.1002/(ISSN)1099-1557</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/pds.2114</json:string></doi><id>E6859C2E262862C6FD9A0C74E7103DF47E68A69C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E6859C2E262862C6FD9A0C74E7103DF47E68A69C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E6859C2E262862C6FD9A0C74E7103DF47E68A69C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E6859C2E262862C6FD9A0C74E7103DF47E68A69C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Utilization of anti‐Parkinson drugs in Australia: 1995–2009</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Ltd</publisher><pubPlace>Chichester, UK</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Utilization of anti‐Parkinson drugs in Australia: 1995–2009</title><author><persName><forename type="first">Samantha A</forename><surname>Hollingworth</surname></persName><note type="biography">Senior Research Fellow.</note><affiliation>Senior Research Fellow.</affiliation><note type="correspondence"><p>Correspondence: The University of Queensland, School of Population Health, Herston Road, Herston QLD 4006, Australia.</p></note><affiliation>The University of Queensland, School of Population Health, Herston, Australia</affiliation></author><author><persName><forename type="first">Amanda</forename><surname>Rush</surname></persName><note type="biography">Research Assistant.</note><affiliation>Research Assistant.</affiliation><affiliation>The University of Queensland, School of Population Health, Herston, Australia</affiliation></author><author><persName><forename type="first">Wayne D</forename><surname>Hall</surname></persName><note type="biography">NHMRC Australia Fellow and Professor of Public Health Policy.</note><affiliation>NHMRC Australia Fellow and Professor of Public Health Policy.</affiliation><affiliation>The University of Queensland, UQ Centre for Clinical Research, Herston, Australia</affiliation></author><author><persName><forename type="first">Mervyn J</forename><surname>Eadie</surname></persName><note type="biography">Emeritus Professor of Clinical Neurology and Neuropharmacology.</note><affiliation>Emeritus Professor of Clinical Neurology and Neuropharmacology.</affiliation><affiliation>The University of Queensland, School of Medicine, Herston, Australia</affiliation></author></analytic><monogr><title level="j">Pharmacoepidemiology and Drug Safety</title><title level="j" type="abbrev">Pharmacoepidem. Drug Safe.</title><idno type="pISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><idno type="DOI">10.1002/(ISSN)1099-1557</idno><imprint><publisher>John Wiley & Sons, Ltd</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2011-05"></date><biblScope unit="volume">20</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="450">450</biblScope><biblScope unit="page" to="456">456</biblScope></imprint></monogr><idno type="istex">E6859C2E262862C6FD9A0C74E7103DF47E68A69C</idno><idno type="DOI">10.1002/pds.2114</idno><idno type="ArticleID">PDS2114</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Purpose: To examine trends in the prescribing of anti‐Parkinsonian drugs (APD) in Australia from 1995 to 2009. Methods: We analyzed the Medicare Australia and Drug Utilisation Sub‐Committee (DUSC) databases for prescription data for overall APD dispensed use from 1995. We were able to examine prescribing by gender, age, and type of prescriber between 2002 and 2009. Prescriptions were converted to defined daily doses (DDD)/1000 population/day using Australian Bureau of Statistics population data. Results: Dispensed use of levodopa + carbidopa remained steady from 1995 to 2009 (0.76–0.82 DDD/1000 population/day); levodopa + benserazide use increased from 0.34 to 0.55 DDD/1000 population/day. Since 2005 dispensed use of levodopa + carbidopa + entacapone has steadily increased, from 0.03 to 0.10 DDD/1000 population/day. In July 2009 levodopa + carbidopa was the most widely used agent, followed by levodopa + benserazide, then benztropine. Cabergoline increased from 1999, peaked in 2006, and thereafter declined. APD use peaked in males and females aged 60–69 years. Age‐adjusted utilization was slightly higher in males than females. Conclusions: The amount of levodopa dispensed has slowly increased with levodopa + benserazide increasing faster than levodopa + carbidopa. Use of cabergoline fell when pramipexole became available and the risk of ergot‐related serosal adverse effects was more widely appreciated. Use of centrally acting anti‐cholinergics decreased over a period of time when use of atypical anti‐psychotic agents increased. Copyright © 2011 John Wiley & Sons, Ltd.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>anti‐Parkinson drugs</term></item><item><term>utilization</term></item><item><term>prescribing</term></item><item><term>Parkinson's disease</term></item><item><term>pharmacoepidemiology</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Original Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-06-22">Received</change><change when="2011-01-08">Registration</change><change when="2011-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E6859C2E262862C6FD9A0C74E7103DF47E68A69C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component type="serialArticle" version="2.0" xml:lang="en" xml:id="pds2114"><header xml:id="pds2114-hdr-0001"><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Ltd</publisherName><publisherLoc>Chichester, UK</publisherLoc></publisherInfo><doi>10.1002/(ISSN)1099-1557</doi><issn type="print">1053-8569</issn><issn type="electronic">1099-1557</issn><idGroup><id type="product" value="PDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="PHARMACOEPIDEMIOLOGY AND DRUG SAFETY">Pharmacoepidemiology and Drug Safety</title><title type="short">Pharmacoepidem. Drug Safe.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi>10.1002/pds.v20.5</doi><copyright ownership="publisher">Copyright © 2011 John Wiley & Sons, Ltd.</copyright><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2011-05">May 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="2" status="forIssue"><doi>10.1002/pds.2114</doi><idGroup><id type="unit" value="PDS2114"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Original Report</title><title type="tocHeading1">Original Reports</title></titleGroup><copyright ownership="publisher">Copyright © 2011 John Wiley & Sons, Ltd.</copyright><eventGroup><event type="manuscriptReceived" date="2010-06-22"></event><event type="manuscriptRevised" date="2010-12-14"></event><event type="manuscriptAccepted" date="2011-01-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.25.1 mode:FullText" date="2011-04-21"></event><event type="xmlCorrected" agent="SPi Global" date="2011-04-21"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-02-15"></event><event type="firstOnline" date="2011-02-15"></event><event type="publishedOnlineFinalForm" date="2011-04-26"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst">450</numbering><numbering type="pageLast">456</numbering></numberingGroup><correspondenceTo>The University of Queensland, School of Population Health, Herston Road, Herston QLD 4006, Australia.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:PDS.PDS2114.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="main" xml:lang="en">Utilization of anti‐Parkinson drugs in Australia: 1995–2009</title><title type="short" xml:lang="en">ANTI‐PARKINSON DRUGS IN AUSTRALIA</title></titleGroup><creators><creator xml:id="pds2114-cr-0001" creatorRole="author" affiliationRef="#pds2114-aff-0001" corresponding="yes" noteRef="#pds2114-note-0001"><personName><givenNames>Samantha A</givenNames><familyName>Hollingworth</familyName></personName><contactDetails><email>s.hollingworth@uq.edu.au</email></contactDetails></creator><creator xml:id="pds2114-cr-0002" creatorRole="author" affiliationRef="#pds2114-aff-0001" noteRef="#pds2114-note-0002"><personName><givenNames>Amanda</givenNames><familyName>Rush</familyName></personName></creator><creator xml:id="pds2114-cr-0003" creatorRole="author" affiliationRef="#pds2114-aff-0002" noteRef="#pds2114-note-0003"><personName><givenNames>Wayne D</givenNames><familyName>Hall</familyName></personName></creator><creator xml:id="pds2114-cr-0004" creatorRole="author" affiliationRef="#pds2114-aff-0003" noteRef="#pds2114-note-0004"><personName><givenNames>Mervyn J</givenNames><familyName>Eadie</familyName></personName></creator></creators><affiliationGroup xml:id="pds2114-affgp-0001"><affiliation xml:id="pds2114-aff-0001" countryCode="AU" type="organization"><unparsedAffiliation>The University of Queensland, School of Population Health, Herston, Australia</unparsedAffiliation></affiliation><affiliation xml:id="pds2114-aff-0002" countryCode="AU" type="organization"><unparsedAffiliation>The University of Queensland, UQ Centre for Clinical Research, Herston, Australia</unparsedAffiliation></affiliation><affiliation xml:id="pds2114-aff-0003" countryCode="AU" type="organization"><unparsedAffiliation>The University of Queensland, School of Medicine, Herston, Australia</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="pds2114-kwd-0001">anti‐Parkinson drugs</keyword><keyword xml:id="pds2114-kwd-0002">utilization</keyword><keyword xml:id="pds2114-kwd-0003">prescribing</keyword><keyword xml:id="pds2114-kwd-0004">Parkinson's disease</keyword><keyword xml:id="pds2114-kwd-0005">pharmacoepidemiology</keyword></keywordGroup><abstractGroup><abstract xml:id="pds2114-abs-0001" type="main" xml:lang="en"><title type="main">ABSTRACT</title><section xml:id="pds2114-sec-0001"><title type="main">Purpose</title><p xml:id="pds2114-para-0001">To examine trends in the prescribing of anti‐Parkinsonian drugs (APD) in Australia from 1995 to 2009.</p></section><section xml:id="pds2114-sec-0002"><title type="main">Methods</title><p xml:id="pds2114-para-0002">We analyzed the Medicare Australia and Drug Utilisation Sub‐Committee (DUSC) databases for prescription data for overall APD dispensed use from 1995. We were able to examine prescribing by gender, age, and type of prescriber between 2002 and 2009. Prescriptions were converted to defined daily doses (DDD)/1000 population/day using Australian Bureau of Statistics population data.</p></section><section xml:id="pds2114-sec-0003"><title type="main">Results</title><p xml:id="pds2114-para-0003">Dispensed use of levodopa + carbidopa remained steady from 1995 to 2009 (0.76–0.82 DDD/1000 population/day); levodopa + benserazide use increased from 0.34 to 0.55 DDD/1000 population/day. Since 2005 dispensed use of levodopa + carbidopa + entacapone has steadily increased, from 0.03 to 0.10 DDD/1000 population/day. In July 2009 levodopa + carbidopa was the most widely used agent, followed by levodopa + benserazide, then benztropine. Cabergoline increased from 1999, peaked in 2006, and thereafter declined. APD use peaked in males and females aged 60–69 years. Age‐adjusted utilization was slightly higher in males than females.</p></section><section xml:id="pds2114-sec-0004"><title type="main">Conclusions</title><p xml:id="pds2114-para-0004">The amount of levodopa dispensed has slowly increased with levodopa + benserazide increasing faster than levodopa + carbidopa. Use of cabergoline fell when pramipexole became available and the risk of ergot‐related serosal adverse effects was more widely appreciated. Use of centrally acting anti‐cholinergics decreased over a period of time when use of atypical anti‐psychotic agents increased. Copyright © 2011 John Wiley & Sons, Ltd.</p></section></abstract></abstractGroup></contentMeta><noteGroup xml:id="pds2114-ntgp-0001"><note xml:id="pds2114-note-0001"><p xml:id="pds2114-para-0005">Senior Research Fellow.</p></note><note xml:id="pds2114-note-0002"><p xml:id="pds2114-para-0006">Research Assistant.</p></note><note xml:id="pds2114-note-0003"><p xml:id="pds2114-para-0007">NHMRC Australia Fellow and Professor of Public Health Policy.</p></note><note xml:id="pds2114-note-0004"><p xml:id="pds2114-para-0008">Emeritus Professor of Clinical Neurology and Neuropharmacology.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Utilization of anti‐Parkinson drugs in Australia: 1995–2009</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>ANTI‐PARKINSON DRUGS IN AUSTRALIA</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Utilization of anti‐Parkinson drugs in Australia: 1995–2009</title></titleInfo><name type="personal"><namePart type="given">Samantha A</namePart><namePart type="family">Hollingworth</namePart><affiliation>The University of Queensland, School of Population Health, Herston, Australia</affiliation><description>Senior Research Fellow.</description><description>Correspondence: The University of Queensland, School of Population Health, Herston Road, Herston QLD 4006, Australia.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Amanda</namePart><namePart type="family">Rush</namePart><affiliation>The University of Queensland, School of Population Health, Herston, Australia</affiliation><description>Research Assistant.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wayne D</namePart><namePart type="family">Hall</namePart><affiliation>The University of Queensland, UQ Centre for Clinical Research, Herston, Australia</affiliation><description>NHMRC Australia Fellow and Professor of Public Health Policy.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mervyn J</namePart><namePart type="family">Eadie</namePart><affiliation>The University of Queensland, School of Medicine, Herston, Australia</affiliation><description>Emeritus Professor of Clinical Neurology and Neuropharmacology.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>John Wiley & Sons, Ltd</publisher><place><placeTerm type="text">Chichester, UK</placeTerm></place><dateIssued encoding="w3cdtf">2011-05</dateIssued><dateCaptured encoding="w3cdtf">2010-06-22</dateCaptured><dateValid encoding="w3cdtf">2011-01-08</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Purpose: To examine trends in the prescribing of anti‐Parkinsonian drugs (APD) in Australia from 1995 to 2009. Methods: We analyzed the Medicare Australia and Drug Utilisation Sub‐Committee (DUSC) databases for prescription data for overall APD dispensed use from 1995. We were able to examine prescribing by gender, age, and type of prescriber between 2002 and 2009. Prescriptions were converted to defined daily doses (DDD)/1000 population/day using Australian Bureau of Statistics population data. Results: Dispensed use of levodopa + carbidopa remained steady from 1995 to 2009 (0.76–0.82 DDD/1000 population/day); levodopa + benserazide use increased from 0.34 to 0.55 DDD/1000 population/day. Since 2005 dispensed use of levodopa + carbidopa + entacapone has steadily increased, from 0.03 to 0.10 DDD/1000 population/day. In July 2009 levodopa + carbidopa was the most widely used agent, followed by levodopa + benserazide, then benztropine. Cabergoline increased from 1999, peaked in 2006, and thereafter declined. APD use peaked in males and females aged 60–69 years. Age‐adjusted utilization was slightly higher in males than females. Conclusions: The amount of levodopa dispensed has slowly increased with levodopa + benserazide increasing faster than levodopa + carbidopa. Use of cabergoline fell when pramipexole became available and the risk of ergot‐related serosal adverse effects was more widely appreciated. Use of centrally acting anti‐cholinergics decreased over a period of time when use of atypical anti‐psychotic agents increased. Copyright © 2011 John Wiley & Sons, Ltd.</abstract><subject lang="en"><genre>Keywords</genre><topic>anti‐Parkinson drugs</topic><topic>utilization</topic><topic>prescribing</topic><topic>Parkinson's disease</topic><topic>pharmacoepidemiology</topic></subject><relatedItem type="host"><titleInfo><title>Pharmacoepidemiology and Drug Safety</title></titleInfo><titleInfo type="abbreviated"><title>Pharmacoepidem. Drug Safe.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Original Report</topic></subject><identifier type="ISSN">1053-8569</identifier><identifier type="eISSN">1099-1557</identifier><identifier type="DOI">10.1002/(ISSN)1099-1557</identifier><identifier type="PublisherID">PDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>450</start><end>456</end><total>7</total></extent></part></relatedItem><identifier type="istex">E6859C2E262862C6FD9A0C74E7103DF47E68A69C</identifier><identifier type="DOI">10.1002/pds.2114</identifier><identifier type="ArticleID">PDS2114</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 John Wiley & Sons, Ltd.Copyright © 2011 John Wiley & Sons, Ltd.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>John Wiley & Sons, Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B77 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000B77 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:E6859C2E262862C6FD9A0C74E7103DF47E68A69C
|texte= Utilization of anti‐Parkinson drugs in Australia: 1995–2009
}}
| This area was generated with Dilib version V0.6.23. |  |